Literature DB >> 19495806

Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation.

Michal Malina1, Ondrej Cinek, Jan Janda, Tomas Seeman.   

Abstract

Autosomal recessive steroid-resistant nephrotic syndrome (NS) is a rare, genetically determined nephropathy caused mainly by a mutation in the NPHS2 gene. This type of NS is usually resistant to other immunosuppressive therapy as well, but a few cases of cyclosporine A-induced partial remission of inherited NS have been reported. We present a boy that developed NS at the age of 18 months. There was no decrease of proteinuria on standard prednisolone therapy, and a diagnosis of steroid-resistant NS was established. However, the proteinuria decreased significantly following the initiation of cyclosporine A therapy (from 1280 to 380 mg/m(2) per day) without any negative effects on renal function (stable glomerular filtration rate 130-150 ml/min per 1.73 m(2)). The molecular genetic test revealed a homozygous R138Q mutation in the NPHS2 gene. Our case demonstrates that cyclosporine A can induce partial remission in patients with genetic forms of NS without influencing the glomerular filtration rate. However, its long-term effect and safety in children with hereditary forms of nephrotic syndrome have yet to be investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495806     DOI: 10.1007/s00467-009-1211-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

Review 1.  Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

Authors:  E M Hodson; D Habashy; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2).

Authors:  Bernward G Hinkes; Bettina Mucha; Christopher N Vlangos; Rasheed Gbadegesin; Jinhong Liu; Katrin Hasselbacher; Daniela Hangan; Fatih Ozaltin; Martin Zenker; Friedhelm Hildebrandt
Journal:  Pediatrics       Date:  2007-03-19       Impact factor: 7.124

3.  Cyclosporin therapy in patients with Alport syndrome.

Authors:  Marina Charbit; Marie-Claire Gubler; Michèle Dechaux; Marie-France Gagnadoux; Jean-Pierre Grünfeld; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

4.  Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model.

Authors:  Dilys Chen; Barbara Jefferson; Scott J Harvey; Keqin Zheng; Cathy J Gartley; Robert M Jacobs; Paul S Thorner
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

5.  Long-term effects of cyclosporine A in Alport's syndrome.

Authors:  L Callís; A Vila; M Carrera; J Nieto
Journal:  Kidney Int       Date:  1999-03       Impact factor: 10.612

6.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

Authors:  Rainer G Ruf; Anne Lichtenberger; Stephanie M Karle; Johannes P Haas; Franzisco E Anacleto; Michael Schultheiss; Isabella Zalewski; Anita Imm; Eva-Maria Ruf; Bettina Mucha; Arvind Bagga; Thomas Neuhaus; Arno Fuchshuber; Aysin Bakkaloglu; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

7.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

Authors:  Christian Faul; Mary Donnelly; Sandra Merscher-Gomez; Yoon Hee Chang; Stefan Franz; Jacqueline Delfgaauw; Jer-Ming Chang; Hoon Young Choi; Kirk N Campbell; Kwanghee Kim; Jochen Reiser; Peter Mundel
Journal:  Nat Med       Date:  2008-09       Impact factor: 53.440

8.  Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated.

Authors:  Jochen H H Ehrich; Christoph Geerlings; Miroslav Zivicnjak; Doris Franke; Heinz Geerlings; Jutta Gellermann
Journal:  Nephrol Dial Transplant       Date:  2007-05-15       Impact factor: 5.992

9.  WT1 and NPHS2 mutations in Korean children with steroid-resistant nephrotic syndrome.

Authors:  Hee Yeon Cho; Joo Hoon Lee; Hyun Jin Choi; Bum Hee Lee; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2007-10-13       Impact factor: 3.714

10.  Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.

Authors:  Beom Seok Kim; Hyeong Cheon Park; Shin Wook Kang; Kyu Hun Choi; Sung Kyu Ha; Dae Suk Han; Ho Yung Lee
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

  10 in total
  20 in total

Review 1.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

2.  Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression.

Authors:  Sabrina Giglio; Aldesia Provenzano; Benedetta Mazzinghi; Francesca Becherucci; Laura Giunti; Giulia Sansavini; Fiammetta Ravaglia; Rosa Maria Roperto; Silvia Farsetti; Elisa Benetti; Mario Rotondi; Luisa Murer; Elena Lazzeri; Laura Lasagni; Marco Materassi; Paola Romagnani
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

Review 3.  Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

Review 4.  Podocytes from the diagnostic and therapeutic point of view.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pflugers Arch       Date:  2017-05-16       Impact factor: 3.657

Review 5.  Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Elisabeth M Hodson; Debbie S Gipson
Journal:  Pediatr Nephrol       Date:  2012-10-05       Impact factor: 3.714

Review 6.  The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.

Authors:  Constantinos J Stefanidis; Uwe Querfeld
Journal:  Eur J Pediatr       Date:  2011-02-08       Impact factor: 3.183

7.  Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.

Authors:  Albert Bensman; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2010-03-02       Impact factor: 3.714

8.  Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

Authors:  Agnes Trautmann; Sven Schnaidt; Beata S Lipska-Ziętkiewicz; Monica Bodria; Fatih Ozaltin; Francesco Emma; Ali Anarat; Anette Melk; Marta Azocar; Jun Oh; Bassam Saeed; Alaleh Gheisari; Salim Caliskan; Jutta Gellermann; Lina Maria Serna Higuita; Augustina Jankauskiene; Dorota Drozdz; Sevgi Mir; Ayse Balat; Maria Szczepanska; Dusan Paripovic; Alexandra Zurowska; Radovan Bogdanovic; Alev Yilmaz; Bruno Ranchin; Esra Baskin; Ozlem Erdogan; Giuseppe Remuzzi; Agnieszka Firszt-Adamczyk; Elzbieta Kuzma-Mroczkowska; Mieczyslaw Litwin; Luisa Murer; Marcin Tkaczyk; Helena Jardim; Anna Wasilewska; Nikoleta Printza; Kibriya Fidan; Eva Simkova; Halina Borzecka; Hagen Staude; Katharina Hees; Franz Schaefer
Journal:  J Am Soc Nephrol       Date:  2017-05-31       Impact factor: 10.121

Review 9.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

Review 10.  Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations.

Authors:  Geneviève Benoit; Eduardo Machuca; Corinne Antignac
Journal:  Pediatr Nephrol       Date:  2010-03-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.